Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Int J Mol Sci. 2024 Sep 19;25(18):10064. doi: 10.3390/ijms251810064.
In vivo proton (H) magnetic resonance spectroscopy (MRS) is a powerful non-invasive method that can measure Alzheimer's disease (AD)-related neuropathological alterations at the molecular level. AD biomarkers include amyloid-beta (Aβ) plaques and hyperphosphorylated tau neurofibrillary tangles. These biomarkers can be detected via postmortem analysis but also in living individuals through positron emission tomography (PET) or biofluid biomarkers of Aβ and tau. This review offers an overview of biochemical abnormalities detected by H MRS within the biologically defined AD spectrum. It includes a summary of earlier studies that explored the association of H MRS metabolites with biofluid, PET, and postmortem AD biomarkers and examined how apolipoprotein 4 allele carrier status influences brain biochemistry. Studying these associations is crucial for understanding how AD pathology affects brain homeostasis throughout the AD continuum and may eventually facilitate the development of potential novel therapeutic approaches.
体内质子（H）磁共振波谱（MRS）是一种强大的非侵入性方法，可在分子水平上测量与阿尔茨海默病（AD）相关的神经病理学改变。AD 生物标志物包括淀粉样β（Aβ）斑块和过度磷酸化的 tau 神经原纤维缠结。这些生物标志物可以通过死后分析检测，也可以通过正电子发射断层扫描（PET）或 Aβ和 tau 的生物流体生物标志物在活体个体中检测到。本综述概述了 H MRS 在生物学定义的 AD 谱中检测到的生化异常。它总结了早期研究，这些研究探讨了 H MRS 代谢物与生物流体、PET 和死后 AD 生物标志物的关联，并研究了载脂蛋白 4 等位基因携带者状态如何影响大脑生物化学。研究这些关联对于了解 AD 病理学如何影响 AD 连续体中大脑的内稳态至关重要，并且最终可能有助于开发潜在的新型治疗方法。
